Division of Hematology, Department of Internal Medicine, Koç University School of Medicine, Istanbul, Turkey.
Department of Internal Medicine, Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul, South Korea.
Leuk Lymphoma. 2022 Dec;63(14):3317-3330. doi: 10.1080/10428194.2022.2126281. Epub 2022 Oct 6.
Information on Hodgkin lymphoma (HL) is mostly limited to Europe and North America. This real-world, retrospective study assessed treatment pathways and clinical outcomes in adults with stage IIB-IV classical HL receiving frontline treatment ( = 1598) or relapsed/refractory HL (RRHL, = 426) in regions outside Europe and North America between January 2010 and December 2013. The primary endpoint was progression-free survival (PFS) in the RRHL group. Among patients with RRHL, 89.0% received salvage chemotherapy; most common regimen was etoposide, methylprednisolone, cytarabine, cisplatin (ESHAP; 26.3%). Median PFS in the RRHL group was 13.2 months (95% confidence interval [CI]: 9.9-20.2) and was longer in patients with without stem cell transplantation (SCT; 20.6 7.5 months; = 0.0071). This large-scale study identified a lower PFS for RRHL in the rest of the world compared with Europe and North America, highlighting the need for novel targeted therapies and SCT earlier in the treatment continuum. NCT03327571.
关于霍奇金淋巴瘤（HL）的信息主要局限于欧洲和北美。这项真实世界、回顾性研究评估了 2010 年 1 月至 2013 年 12 月期间，在欧洲和北美以外地区接受一线治疗（ = 1598 例）或复发/难治性 HL（RRHL， = 426 例）的 IIB-IV 期经典 HL 成人患者的治疗途径和临床结局。主要终点是 RRHL 组的无进展生存期（PFS）。在 RRHL 患者中，89.0%接受了挽救化疗；最常见的方案是依托泊苷、甲基强的松龙、阿糖胞苷、顺铂（ESHAP；26.3%）。RRHL 组的中位 PFS 为 13.2 个月（95%置信区间 [CI]：9.9-20.2），无干细胞移植（SCT）患者的 PFS 更长（20.6 7.5 个月； = 0.0071）。这项大规模研究发现，与欧洲和北美相比，世界其他地区 RRHL 的 PFS 较低，这突出表明需要新型靶向治疗和更早地在治疗连续体中进行 SCT。NCT03327571。
